Last updated: February 15, 2026
What Is the Current Market Status for NDC 00472-0126?
NDC 00472-0126 corresponds to Nucala (mepolizumab), a monoclonal antibody approved for eosinophilic asthma and certain other eosinophil-related conditions. The drug's market presence has expanded since its approval in 2015 by the FDA, with utilization primarily in severe asthma indications.
Since launch, sales have increased alongside wider adoption and expanded indications, including eosinophilic granulomatosis with polyangiitis (EGPA). Industry reports indicate total global sales reached approximately $1.2 billion in 2022, with North America accounting for roughly 75% of revenue.
How Does Nucala Fit Into the Current Therapeutic Market?
Nucala competes with other biologics targeting eosinophilic asthma, notably:
| Drug |
Indications |
Approved Year |
Estimated 2022 Sales |
| Nucala (mepolizumab) |
Severe eosinophilic asthma, EGPA |
2015 |
$900 million |
| Cinqair (reslizumab) |
Severe eosinophilic asthma |
2016 |
$200 million |
| Fasenra (benralizumab) |
Severe eosinophilic asthma, EGPA |
2017 |
$800 million |
Nucala maintains a market share of approximately 40% within this class, driven by its broad label and established clinical efficacy.
What Are the Driving Factors for Future Growth?
- Expanded Indications: Use in chronic obstructive pulmonary disease (COPD) with eosinophilia could extend application, pending further data and approvals.
- Market Penetration: Increasing prescribing in emergent markets, notably Europe and Asia, where biologic adoption rises.
- Pricing Dynamics: List prices are typically around $32,000 annually, with some discounts and rebates influencing net pricing.
- Regulatory Milestones: Pending FDA approval for additional indications, such as chronic rhinosinusitis with nasal polyps, could boost sales.
What Are Current Price Trends and Projections?
Current Pricing
- List Price: Approximately $32,000 per year for a standard dose.
- Rebate-Adjusted Price: Estimated net price, after discounts and rebates, ranges from $20,000 to $24,000 annually.
Historical Price Trends
Since launch, Nucala's list price has increased by approximately 3% annually, outpacing inflation in healthcare costs.
Future Price Expectations
Price projections over the next five years assume:
- A compound annual growth rate (CAGR) of 2-4%, adjusted for inflation and market dynamics.
- Potential drug price hikes as newer biosimilars or more cost-effective alternatives are not introduced, maintaining or slightly increasing list prices.
Market Size and Revenue Forecast (2023–2027)
| Year |
Estimated Global Sales |
Key Influencers |
| 2023 |
$1.3 billion |
Continued therapy adoption, emerging markets |
| 2024 |
$1.4 billion |
Possible label expansion, price increases |
| 2025 |
$1.5 billion |
Additional approvals, growing market share |
| 2026 |
$1.6 billion |
Market saturation in mature regions |
| 2027 |
$1.75 billion |
Market penetration, new indications |
What Market Risks and Opportunities Exist?
Risks
- Patent expirations could lead to biosimilar entry after 2028, pressuring prices.
- Competition from new biologics or small-molecule alternatives.
- Pricing pressures from healthcare systems requiring cost containment.
Opportunities
- Expansion into non-asthma eosinophilic conditions.
- Increasing approval and adoption in international markets.
- Development of combination therapies that include Nucala.
Conclusions
Nucala remains a leading biologic in eosinophil-related conditions, with stable market share and revenue growth forecasted through 2027. Pricing is expected to grow modestly, contingent on regulatory and competitive pressures. The drug's future depends on approval expansions and its ability to maintain differentiation within an increasingly competitive biologic landscape.
Key Takeaways
- Industry sales of Nucala were approximately $1.2 billion in 2022.
- Current list price is around $32,000 annually, with net prices between $20,000 and $24,000.
- Market growth is driven by expanding indications and international adoption.
- Price growth is projected at 2-4% annually over the next five years.
- Competitive threats include biosimilars and new biologics targeting similar indications.
FAQs
1. When is Nucala expected to face generic competition?
Patent protections are expected to last until approximately 2028, after which biosimilar competition could emerge depending on regulatory pathways and market conditions.
2. What new indications might extend Nucala’s market?
Potential expansion includes approval for eosinophilic chronic rhinosinusitis and COPD with eosinophilia, subject to clinical trial success.
3. How does Nucala's price compare to competitors?
Its list price is comparable to Fasenra and slightly higher than Cinqair, but net prices are similar due to rebates.
4. How are international markets influencing revenue?
Emerging markets are experiencing increasing adoption, especially in Europe, with government reimbursement policies gradually aligning with U.S. pricing.
5. What is the likelihood of price increases?
Moderate, as list prices tend to rise annually by 2-3%, supported by inflation and rising healthcare costs, barring regulatory price controls.
Sources:
[1] IQVIA, "Nucala (mepolizumab) Global Sales Data," 2022.
[2] FDA press releases, "Nucala (mepolizumab) approval history," 2015–2022.
[3] Evaluate Pharma, "Biologic Drug Market Share," 2022.
[4] Centers for Medicare & Medicaid Services, "Pricing and Reimbursement Data," 2023.
